Published • loading... • Updated
[Opinion] Amgen’s Repatha Receives Positive CHMP Opinion for Broader Cardiovascular Use
Summary by Pharmaceutical Business Review
3 Articles
3 Articles
Apolipoprotein B should be measured in risk groups, a US study concludes.
·Helsinki, Finland
Read Full Article
Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use
Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels, The post Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use appeared first on Pharmaceutical Business review.
Cholesterol is often the usual enemy when we talk about cardiovascular health. The bad thing is that we put aside many other concepts, believing that only [...]
·Madrid, Spain
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
